| Cat.No. | Name | Information |
|---|---|---|
| M1781 | Adezmapimod (SB203580) | Adezmapimod (SB203580) is a P38 MAPK inhibitor with an IC50 of 0.3-0.5 μM, which is 10 times less selective than SAPK3(106T) and SAPK4(106T), and inhibits PKB phosphorylation with an IC50 of 3-5 μM. |
| M2062 | SB 202190 | SB 202190 is a highly selective, potent and cell permeable inhibitor of p38 MAP kinase with IC50 values of 50 and 100 nM inhibiting p38α and p38β, respectively. |
| M1675 | BIRB796 | BIRB 796 (Doramapimod) is a protein kinase inhibitor of p38 MAPK with Kd of 100pM. |
| M1556 | Hesperetin | Hesperetin is a potent and broad-spectrum inhibitor against human UGT activity. |
| M45284 | AMG-548 dihydrochloride | AMG-548 dihydrochloride is an orally active, selective inhibitor of p38α (Ki=0.5 nM), slightly selective for p38β (Ki=36 nM), and >1000-fold selective for p38γ and p38δ. AMG-548 dihydrochloride also potently inhibits whole blood LPS-stimulated TNFα (IC50=3 nM). LPS-stimulated TNFα (IC50=3 nM). In addition, AMG-548 dihydrochloride inhibits Wnt signaling through direct inhibition of Casein kinase 1 isoforms δ and ε. |
| M44944 | Natsudaidain | Natsudaidain is a kind of polymethoxyflavone. |
| M44747 | 5,6,7-Trimethoxyflavone | 5,6,7-Trimethoxyflavone is a novel p38-α MAPK inhibitor with an anti-inflammatory effect. |
| M44718 | 3,5-Di-O-caffeoylquinic acid methyl ester | Macranthoin G is an inhibitor of p38 MAPK. |
| M42151 | p38 Kinase inhibitor 5 | p38 Kinase inhibitor 5 (AA6) is a potent p38 kinase inhibitor with an IC50 of 403.57 nM. |
| M42150 | p38α inhibitor 4 | p38α inhibitor 4 is a selective and allosteric p38α inhibitor with an IC50 value of 1.2 μM. |
| M42149 | SX 011 | SX 011 is a p38 inhibitor with IC50s of 9 nM and 90 nM against p38α and p38β, respectively. |
| M42148 | Akt/NF-κB/MAPK-IN-1 | Akt/NF-κB/MAPK-IN-1 is a potent and orally active inhibitor against NO (IC50=7.70 μM) with no significant toxicity. |
| M42146 | SB 220025 | SB 220025 is a reversible, orally active, cell-permeable, ATP-competitive and selective human p38 MAPK inhibitor (IC50 = 60 nM). |
| M39018 | Sugiol | Sugiol is an abietane diterpenoid, can be isolated from Calocedrus formosana bark. Sugiol has anti-inflammatory activity, could effectively reduce intracellular reactive oxygen species (ROS) production in lipopolysaccharide (LPS)-stimulated macrophages. |
| M39017 | Emodic acid | Emodic acid (NSC624610) inhibits the proliferation of cancer cells by inhibiting the activity of NF-κB. Emodic acid can also inhibit the phosphorylation of p38, ERK and JNK, the secretion of tumor-promoting cytokines IL-1β and IL-6, and the expression of VEGF and MMP. |
| M39016 | Isodorsmanin A | Isodorsmanin A is an anti-inflammatory agent. Isodorsmanin A suppresses the production of inflammatory mediators and proinflammatory cytokines. Isodorsmanin A inhibits the phosphorylation of JNK, MAPK. |
| M39015 | Deoxysappanone B | Deoxysappanone B has anti-neuroinflammatory and neuroprotective effects and inhibits the production of neuroinflammatory mediators by blocking the IκB kinase (IKK)-NF-κB and p38/ERK MAPK pathways. Deoxysappanone B can be used in disease studies of neuritis and inflammation-related neurological damage. |
| M31047 | Emprumapimod hydrochloride | Emprumapimod (PF-07265803) hydrochloride is an orally active and selective inhibitor of p38α MAPK. Emprumapimod hydrochloride can be used for the research of dilated cardiomyopathy and acute inflammatory pain. |
| M30721 | Ralimetinib | Ralimetinib (LY2228820) is a potent and selective, ATP-competitive inhibitor of p38 MAPK α/β, with IC50s of 5.3 and 3.2 nM, respectively. Ralimetinib (LY2228820) selectively inhibits phosphorylation of MK2 (Thr334), with no effect on phosphorylation of p38α MAPK, JNK, ERK1/2, c-Jun, ATF2, or c-Myc. |
| M30062 | CMPD1 | CMPD1 is a selective and non-ATP-competitive p38 MAPK-mediated MK2 phosphorylation inhibitor with apparent Ki (Kiapp) of 330 nM. |
| M29960 | SB 202190 hydrochloride | SB 202190 hydrochloride is a selective p38 MAP kinase inhibitor with IC50s of 50 nM and 100 nM for p38α and p38β2, respectively. SB 202190 hydrochloride binds to the ATP pocket of the active recombinant human p38 kinase with a Kd of 38 nM. SB 202190 hydrochloride has anti-cancer activity. SB202190 hydrochloride induces autophagy. |
| M29615 | SR-318 | SR-318 is a potent and highly selective p38 MAPK inhibitor with IC50s of 5 nM, 32 nM and 6.11 μM for p38α, p38β and p38α/β, respectively. SR-318 potently inhibits the TNF-α release in whole blood with an IC50 of 283 nM. SR-318 has anti-cancer and anti-inflammatory activity. |
| M29339 | SB-284851-BT | SB-284851-BT is an inhibitor of BRD4/p38α/BRDT. SB-284851-BT inhibits BRD4-BD1 (IC50=1.7 µM), p38α (Kd=0.47 nM), BRDT (1) (IC50=18 µM) and BRD4 (1)(IC50=3.7 µM). SB-284851-BT reduces IL-8 production by inhibiting p38α, as well as inhibiting BRD4 to down-regulates c-Myc and NF-κB gene pathways in cancer. SB-284851-BT can combined with the bromine domain and extra terminal (BET). |
| M29024 | MW-150 hydrochloride | MW-150 hydrochloride (MW01-18-150SRM hydrochloride) is a selective, CNS penetrant, and orally active inhibitor of p38α MAPK with a Ki of 101 nM. MW-150 hydrochloride (MW01-18-150SRM hydrochloride) inhibits the ability of the endogenous p38α MAPK to phosphorylate an endogenous substrate MK2 in activated glia. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
